Sunitinib Malate APIs from Loncom Pharma are a key component in multi-targeted receptor tyrosine kinase inhibitors, used for renal cell carcinoma and gastrointestinal stromal tumors, demonstrating Loncom Pharma's commitment to comprehensive cancer care.
